# Ferdinand C. Breedveld

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ferdinand-c-breedveld/

## Facts

| Field | Value |
| --- | --- |
| Citations | 34,153 |
| Field | Rheumatoid Arthritis Research and Therapies |
| h-index | 79 |
| i10-index | 167 |
| Last Known Institution | Leiden University |
| OpenAlex ID | https://openalex.org/A5110445652 |
| Works | 224 |

## Researcher papers

- [Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis](https://scholariq.org/papers/infliximab-and-methotrexate-in-the-treatment-of-rheumatoid-arthritis/)
- [Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial](https://scholariq.org/papers/infliximab-chimeric-anti-tumour-necrosis-factor-monoclonal-antibody-versus/)
- [The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment](https://scholariq.org/papers/the-premier-study-a-multicenter-randomized-double-blind-clinical-trial-of/)
- [Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis](https://scholariq.org/papers/therapeutic-efficacy-of-multiple-intravenous-infusions-of-anti-tumor-necrosis/)
- [\nEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.](https://scholariq.org/papers/neular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic/)
- [Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force](https://scholariq.org/papers/treating-rheumatoid-arthritis-to-target-2014-update-of-the-recommendations-of-an/)
- [The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo](https://scholariq.org/papers/the-safety-and-efficacy-of-a-jak-inhibitor-in-patients-with-active-rheumatoid/)

## Researcher topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)

## Researcher university

- [Leiden University](https://scholariq.org/institutions/leiden-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.